[Hidden Champions on the Move] GENUV reports continued progress in Lou Gehrig’s Drug Clinical Trial
2020-12-08
[Hidden Champions on the Move] GENUV reports continued progress in Lou Gehrig’s Drug Clinical Trial
Innovative drug discovery company, GENUV, announced on December 7th that the phase 1/2a clinical trial of its Amyotrophic Lateral Sclerosis (ALS) drug candidate, SNR1611, is progressing smoothly.
SNR1611, a drug candidate that has received IND approval from the Ministry of Food and Drug Safety in September of last year, is being developed as an oral drug that promotes neurogenesis and neural homeostasis recovery.
